<DOC>
	<DOCNO>NCT00451360</DOCNO>
	<brief_summary>We carry 3 year , randomize , double-blind , placebo-controlled , multicenter clinical trial patient hip osteoarthritis order : - evaluate ability diacerein , interleukin-1Î² inhibitor , slow progressive decrease joint space width observe patient hip osteoarthritis - investigate potential structure-modifying effect diacerein patient hip osteoarthritis This study compare also ten year percentage patient treatment group require hip replacement surgery</brief_summary>
	<brief_title>Chondromodulating Effect Diacerein Osteoarthritis Hip</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Diacetylrhein</mesh_term>
	<criteria>Outpatients fulfil American College Rheumatology criterion diagnosis hip osteoarthritis . Lequesne algofunctional index list 3 point . Radiographic criterion inclusion : joint space width ( JSW ) 1 mm 3 mm . If JSW exceed 3 mm , least 0.5 mm thinner JSW contra lateral hip , measure narrow point . Intraarticular injection arthroscopy hip three month prior inclusion study . Any systemic intraarticular corticosteroid well potential symptommodifying drug osteoarthritis allow study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Diacerein</keyword>
	<keyword>Hip osteoarthritis</keyword>
	<keyword>Structure-modifying effect / Chondromodulating effect</keyword>
	<keyword>Double blind study</keyword>
</DOC>